BACKGROUND: Early-onset baldness has been linked to prostate cancer; however, little is known about this relationship in African-Americans who are at elevated prostate cancer risk. METHODS: We recruited 219 African-American controls and 318 African-American prostate cancer cases. We determined age-stratified associations of baldness with prostate cancer occurrence and severity defined by high stage (T3/T4) or high grade (Gleason 7+.) Associations of androgen metabolism genotypes (CYP3A4, CYP3A5, CYP3A43, AR-CAG, SRD5A2 A49T, and SRD5A2 V89L), family history, alcohol intake, and smoking were examined by baldness status and age group by using multivariable logistic regression models. RESULTS: Baldness was associated with odds of prostate cancer [OR = 1.69; 95% confidence interval (CI), 1.05-2.74]. Frontal baldness was associated with high-stage (OR = 2.61; 95% CI, 1.10-6.18) and high-grade (OR = 2.20; 95% CI, 1.05-4.61) tumors. For men diagnosed less than the age of 60 years, frontal baldness was associated with high stage (OR = 6.51; 95% CI, 2.11-20.06) and high grade (OR = 4.23; 95% CI, 1.47-12.14). We also observed a suggestion of an interaction among smoking, median age, and any baldness (P = 0.02). CONCLUSIONS: We observed significant associations between early-onset baldness and prostate cancer in African-American men. Interactions with age and smoking were suggested in these associations. Studies are needed to investigate the mechanisms influencing the relationship between baldness and prostate cancer in African-American men. IMPACT: African-American men present with unique risk factors including baldness patterns that may contribute to prostate cancer disparities.
BACKGROUND: Early-onset baldness has been linked to prostate cancer; however, little is known about this relationship in African-Americans who are at elevated prostate cancer risk. METHODS: We recruited 219 African-American controls and 318 African-American prostate cancer cases. We determined age-stratified associations of baldness with prostate cancer occurrence and severity defined by high stage (T3/T4) or high grade (Gleason 7+.) Associations of androgen metabolism genotypes (CYP3A4, CYP3A5, CYP3A43, AR-CAG, SRD5A2A49T, and SRD5A2V89L), family history, alcohol intake, and smoking were examined by baldness status and age group by using multivariable logistic regression models. RESULTS:Baldness was associated with odds of prostate cancer [OR = 1.69; 95% confidence interval (CI), 1.05-2.74]. Frontal baldness was associated with high-stage (OR = 2.61; 95% CI, 1.10-6.18) and high-grade (OR = 2.20; 95% CI, 1.05-4.61) tumors. For men diagnosed less than the age of 60 years, frontal baldness was associated with high stage (OR = 6.51; 95% CI, 2.11-20.06) and high grade (OR = 4.23; 95% CI, 1.47-12.14). We also observed a suggestion of an interaction among smoking, median age, and any baldness (P = 0.02). CONCLUSIONS: We observed significant associations between early-onset baldness and prostate cancer in African-American men. Interactions with age and smoking were suggested in these associations. Studies are needed to investigate the mechanisms influencing the relationship between baldness and prostate cancer in African-American men. IMPACT: African-American men present with unique risk factors including baldness patterns that may contribute to prostate cancer disparities.
Authors: W Demark-Wahnefried; S M Lesko; M R Conaway; C N Robertson; R V Clark; B Lobaugh; B J Mathias; T S Strigo; D F Paulson Journal: J Androl Date: 1997 Sep-Oct
Authors: B Richards; J Skoletsky; A P Shuber; R Balfour; R C Stern; H L Dorkin; R B Parad; D Witt; K W Klinger Journal: Hum Mol Genet Date: 1993-02 Impact factor: 6.150
Authors: Ruben G Cremers; Katja K Aben; Sita H Vermeulen; Martin den Heijer; Inge M van Oort; Lambertus A Kiemeney Journal: Eur J Cancer Date: 2010-06-17 Impact factor: 9.162
Authors: M Yassa; M Saliou; Y De Rycke; C Hemery; M Henni; J M Bachaud; N Thiounn; J M Cosset; P Giraud Journal: Ann Oncol Date: 2011-02-15 Impact factor: 32.976
Authors: Ethan M Lange; Aruna V Sarma; Anna Ray; Yunfei Wang; Lindsey A Ho; Sarah A Anderson; Julie M Cunningham; Kathleen A Cooney Journal: J Hum Genet Date: 2008-01-24 Impact factor: 3.172
Authors: Rui Li; Felix F Brockschmidt; Amy K Kiefer; Hreinn Stefansson; Dale R Nyholt; Kijoung Song; Sita H Vermeulen; Stavroula Kanoni; Daniel Glass; Sarah E Medland; Maria Dimitriou; Dawn Waterworth; Joyce Y Tung; Frank Geller; Stefanie Heilmann; Axel M Hillmer; Veronique Bataille; Sibylle Eigelshoven; Sandra Hanneken; Susanne Moebus; Christine Herold; Martin den Heijer; Grant W Montgomery; Panos Deloukas; Nicholas Eriksson; Andrew C Heath; Tim Becker; Patrick Sulem; Massimo Mangino; Peter Vollenweider; Tim D Spector; George Dedoussis; Nicholas G Martin; Lambertus A Kiemeney; Vincent Mooser; Kari Stefansson; David A Hinds; Markus M Nöthen; J Brent Richards Journal: PLoS Genet Date: 2012-05-31 Impact factor: 5.917
Authors: Saud Khan; Joshua Caldwell; Travis A Gerke; Sarah C Markt; Kathryn M Wilson; Amparo G Gonzalez-Feliciano; Samuel Peisch; Claire H Pernar; Rebecca E Graff; Edward L Giovannucci; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-10 Impact factor: 4.254
Authors: Cindy Ke Zhou; Alyson J Littman; Paul H Levine; Heather J Hoffman; Sean D Cleary; Emily White; Michael B Cook Journal: Prostate Date: 2014-12-09 Impact factor: 4.104
Authors: Cindy Ke Zhou; Paul H Levine; Sean D Cleary; Heather J Hoffman; Barry I Graubard; Michael B Cook Journal: Am J Epidemiol Date: 2016-01-12 Impact factor: 4.897
Authors: Cindy Ke Zhou; Ruth M Pfeiffer; Sean D Cleary; Heather J Hoffman; Paul H Levine; Lisa W Chu; Ann W Hsing; Michael B Cook Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Kosj Yamoah; Charnita M Zeigler-Johnson; Abra Jeffers; Bruce Malkowicz; Elaine Spangler; Jong Y Park; Alice Whittemore; Timothy R Rebbeck Journal: BMC Cancer Date: 2016-07-29 Impact factor: 4.430